# Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

> clinical trial · VERIFIED · 2026-08-18

Status: ACTIVE_NOT_RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Relapsing Multiple Sclerosis

- Company: Novartis Pharmaceuticals
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT05156281

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.